TEST BANK FOR CLAYTON’S BASIC PHARMACOLOGY FOR
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter 3r01: 3rDrug 3rDefinitions, 3rStandards, 3rand 3rInformation 3rSources
3rWillihnganz: 3rClayton’s 3rBasic 3rPharmacology 3rfor 3rNurses, 3r19th 3rEdition
MULTIPLE
3rCHOICE
1. Which 3rname 3ridentifies 3ra 3rdrug 3rlisted 3rby 3rthe 3rUS
3r Food 3rand3rDrug 3rAdministration 3r(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: 3r C
The 3rofficial 3rname 3ris 3rthe 3 r name 3runder 3rwhich 3ra 3rdrug
3ris 3rlisted 3rby 3rthe 3rFDA. 3rThe 3rbrand 3rname, 3ror 3rtrademark,
3ris 3rthe 3rname 3r given 3rto 3ra 3rdrug 3rby 3rits 3rmanufacturer. 3rThe
3rnonproprietary, 3ror 3rgeneric, 3rname 3ris 3rprovided 3rby 3rthe
3rUnited 3rStates 3rAdopted 3rNames 3rCouncil.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r9
OBJ: 3r1NAT: 3rNCLEX 3rClient 3rNeeds 3rCategory: 3rSafe,
3rEffective 3rCare3rEnvironment 3rTOP: 3 r Nursing 3rProcess 3rStep:
3rAssessment CON:
3rPatient 3rEducation
2. Which 3rsource 3rcontains 3rinformation 3rspecific 3rto 3rnutritional 3rsupplements?
a. USP 3rDictionary 3rof 3rUSAN 3 r &3rInternational 3rDrug 3rNames
b. Natural 3rMedicines 3rComprehensive 3rDatabase
c. United 3rStates 3rPharmacopoeia/National 3rFormulary 3r(USP 3rNF)
d. Drug 3rInteraction 3rFacts
ANS: 3r C
United 3rStates 3rPharmacopoeia/National 3rFormulary 3rcontains 3rinformation 3rspecific 3rto
3rnutritional3rsupplements. 3rUSP 3rDictionary 3rof 3rUSAN 3r & 3rInternational 3rDrug 3rNames 3ris 3ra
3rcompilation 3rof 3rdrug3rnames, 3rpronunciation 3rguide, 3rand 3rpossible 3rfuture 3rFDA 3rapproved
3rdrugs; 3rit 3rdoes 3rnot 3rinclude 3rnutritional 3rsupplements. 3r Natural 3rMedicines 3rComprehensive
3rDatabase 3rcontains
evidence-based 3rinformation 3ron 3rherbal 3rmedicines 3rand 3rherbal 3rcombination 3rproducts; 3rit
3rdoes 3rnot3i
r nclude 3rinformation 3rspecific 3rto 3rnutritional 3rsupplements. 3rDrug 3rInteraction
3rFacts 3rcontains 3rcomprehensive 3rinformation 3ron 3rdrug 3r interaction 3rfacts; 3rit 3r does 3rnot
3r include 3rnutritional 3rsupplements.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r4 OBJ:
3r33rNAT: 3 r NCLEX 3rClient 3rNeeds 3r Category: 3rPhysiological 3rIntegrity
TOP: 3 r Nursing 3rProcess 3rStep: 3rAssessment CON: 3 r Nutrition 3r| 3rPatient 3rEducation
3. Which 3rdrug 3rreference 3rcontains 3rdrug 3rmonographs 3rthat 3rdescribe 3rall 3rdrugs 3rin 3ra 3rtherapeutic 3rclass?
a. Drug 3rFacts 3rand 3rComparisons
,Test 3rBank 3rFor 3rClayton’s 3rBasic 3rPharmacology 3rfor 3rNurses 3r19th 3
3rEdition
b. Drug 3rInteraction 3rFacts
c. Handbook 3ron 3rInjectable 3rDrugs
d. Martindale—The 3rComplete 3rDrug 3rReference
ANS: 3 r A
Drug 3rFacts 3rand 3rComparisons 3rcontains 3rdrug 3rmonographs 3rthat 3rdescribe 3rall
3rdrugs 3rin 3ra3rtherapeutic 3rclass. 3rMonographs 3rare 3rformatted 3ras 3rtables 3rto 3rallow
3rcomparison 3rof 3rsimilar3p r roducts, 3rbrand 3rnames, 3rmanufacturers, 3rcost 3rindices, 3rand
3ravailable 3rdosage 3rforms 3rOnline 3rversion 3ris 3ravailable.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r4 3rTable 3r1.2
OBJ: 3r 3r 3 r 3 NAT: 3 r NCLEX 3rClient 3rNeeds 3rCategory: 3rPhysiological 3rIntegrity
TOP: 3 r Nursing 3rProcess 3rStep: 3rAssessment CON: 3 r Safety 3r| 3rPatient 3rEducation 3r| 3rClinical 3rJudgment
4. Which 3rdrug 3rreference 3rcontains 3rmonographs 3rabout 3r virtually 3revery3rsingle-entity3rdrug
available3rin 3rthe 3rUnited 3rStates 3rand 3rdescribes 3rtherapeutic 3ruses 3rof 3rdrugs, 3rincluding
3r
approved 3rand 3runapproved 3ruses?
3r
a. Martindale: 3rThe 3rComplete 3rDrug 3rReference
b. AHFS 3rDrug 3rInformation
c. Drug 3rReference
d. Drug 3rFacts 3rand 3rComparisons
ANS: 3 r B
AHFS 3rDrug 3rInformation 3rcontains 3rmonographs 3rabout 3rvirtually 3revery 3rsingle-entity 3rdrug
3ravailable 3rin 3rthe 3rUnited 3rStates 3rand 3rdescribes 3rtherapeutic 3ruses 3rof 3rdrugs, 3r including
3rapproved 3rand3u r napproved 3ruses.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r4 3rTable 3r1.2
OBJ: 3r 3r 3 r 3 NAT: 3 r NCLEX 3rClient 3rNeeds 3rCategory: 3rPhysiological 3rIntegrity
TOP: 3 r Nursing 3rProcess 3rStep: 3rPlanning CON: 3 r Safety 3r| 3rPatient 3rEducation 3r| 3rClinical 3rJudgment
5. Which 3ronline 3rdrug 3rreference 3rmakes 3ravailable 3rto 3rhealthcare 3rproviders 3rand 3rthe
3rpublic 3ra 3rstandard, 3rcomprehensive, 3rup-to-date 3rlook 3rup 3rand 3rdownloadable 3rresource
3rabout 3rmedicines?
a. American 3rDrug 3rIndex
b. American 3rHospital 3rFormulary
c. DailyMed
d. Drug 3rReference
ANS: 3r C
DailyMed 3rmakes 3ravailable 3rto 3rhealthcare 3rproviders 3rand 3rthe 3rpublic 3ra 3rstandard,
3rcomprehensive,3rup-to-date 3rlook 3rup 3rand 3rdownloadable 3rresource 3rabout 3rmedicines. 3rThe
3rAmerican 3rDrug 3rIndex 3ris3rnot 3rappropriate 3rfor 3rpatient 3ruse. 3rThe 3rAmerican 3rHospital
3rFormulary 3ris 3rnot 3rappropriate 3rfor 3rpatient 3r use. 3rThe 3rdrug 3rreference 3r is 3r not
3r appropriate 3rfor 3rpatient 3r use.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r3 3r| 3rp. 3r4 OBJ:
3r33rNAT: 3 r NCLEX 3rClient 3rNeeds 3r Category: 3rPhysiological 3rIntegrity
TOP: 3 r Nursing 3rProcess 3rStep: 3rImplementation
CON: 3 r Safety 3r| 3rPatient 3rEducation 3r| 3rClinical 3rJudgment
6. Which 3rlegislation 3rauthorizes 3rthe 3rFDA 3rto 3rdetermine 3rthe 3rsafety3rof 3ra 3rdrug 3rbefore 3rits 3rmarketing?
a. Federal 3rFood, 3rDrug, 3rand 3rCosmetic 3rAct 3r(1938)
b. Durham 3rHumphrey 3rAmendment 3r(1952)
, Test 3rBank 3rFor 3rClayton’s 3rBasic 3rPharmacology 3rfor 3rNurses 3r19th 4
3rEdition
c. Controlled 3rSubstances 3rAct 3r(1970)
d. Kefauver 3rHarris 3rDrug 3rAmendment 3r(1962)
ANS: 3 r A
The 3rFederal 3rFood, 3rDrug, 3rand 3rCosmetic 3rAct 3rof 3r1938 3rauthorized 3rthe 3rFDA 3rto
3rdetermine 3rthe 3rsafety 3rof 3rall 3rdrugs 3rbefore 3rmarketing. 3rLater 3ramendments 3rand 3racts
3rhelped 3rtighten 3rFDA 3rcontrol 3rand 3rensure 3rdrug 3rsafety. 3rThe 3rDurham 3rHumphrey
3rAmendment 3rdefines 3rthe 3rkinds 3rof 3rdrugs 3rthat 3rcannot 3rbe 3rused 3rsafely 3rwithout 3rmedical
3rsupervision 3rand 3rrestricts 3rtheir 3rsale 3rto 3rprescription 3rby 3ra 3rlicensed 3rpractitioner. 3rThe
3rControlled 3rSubstances 3rAct 3raddresses 3ronly 3rcontrolled 3rsubstances 3rand3rtheir
3rcategorization. 3rThe 3rKefauver 3rHarris 3rDrug 3rAmendment 3rensures 3rdrug 3refficacy 3rand
3rgreater3d
r rug 3rsafety. 3rDrug 3rmanufacturers 3rare 3rrequired 3rto 3rprove 3rto 3rthe 3rFDA 3rthe
3reffectiveness 3rof 3rtheir 3rproducts 3rbefore 3rmarketing 3rthem.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3rp. 3r 5 3rTable 3rl.3
OBJ: 3 r 5 NAT: 3rNCLEX 3rClient 3rNeeds 3rCategory: 3rPhysiological
3rIntegrity3T
r OP: 3 r Nursing 3rProcess 3r Step: 3rAssessment
CON: 3 r Safety 3r| 3rPatient 3rEducation 3r| 3rEvidence 3r| 3rHealth 3rCare 3rLaw
7. Which 3rclassification 3rdoes 3rmeperidine 3r(Demerol) 3rfall 3runder?
a. I
b. II
c. III
d. IV
ANS: 3 r B
Meperidine 3r(Demerol) 3ris 3ra 3rSchedule 3rII 3rdrug; 3rit 3rhas 3ra 3rhigh 3rpotential 3rfor 3rabuse 3rand
3rmay 3rlead 3rto3s
r evere 3rpsychological 3rand 3rphysical 3rdependence. 3rSchedule 3rI 3rdrugs 3rhave
3rhigh 3rpotential 3rfor 3rabuse3a
r nd 3rno 3rrecognized 3rmedical 3ruse. 3rSchedule 3rIII 3rdrugs 3rhave
3rsome 3rpotential 3rfor 3rabuse. 3rUse 3rmay 3rlead 3rto 3rlow 3rto 3rmoderate 3rphysical 3rdependence 3ror
3rhigh 3rpsychological 3rdependence. 3rSchedule 3rIV3rdrugs 3rhave 3rlow 3rpotential 3rfor 3rabuse. 3rUse
3rmay 3rlead 3rto 3rlimited 3rphysical 3ror 3rpsychological 3rdependence.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r10 OBJ:
3r23rNAT: 3 r NCLEX 3rClient 3rNeeds 3rCategory: 3rSafe, 3rEffective 3rCare
3rEnvironment
TOP: 3 r Nursing 3rProcess 3rStep: 3rAssessment CON: 3 r Patient 3rEducation 3r| 3rAddiction 3r| 3rPain
8. Which 3raction 3rwould 3rthe 3rFDA 3rtake 3rto 3rexpedite 3rdrug 3rdevelopment 3r and 3rapproval 3rfor 3ran
outbreak3rof 3rsmallpox?
3r
a. List 3rsmallpox 3ras 3ra 3rhealth 3rorphan 3rdisease.
b. Omit 3rthe 3rpreclinical 3rresearch 3rphase.
c. Extend 3rthe 3rclinical 3rresearch 3rphase.
d. Fast 3rtrack 3rthe 3rinvestigational 3rdrug.
ANS: 3r D
Once 3rthe 3rInvestigational 3rNew 3rDrug 3rApplication 3rhas 3rbeen 3rapproved, 3rthe 3rdrug 3rcan
3rreceive 3rhighest 3rpriority 3rwithin 3rthe 3ragency, 3rwhich 3ris 3rcalled 3rfast 3rtracking. 3rA 3rsmallpox
3routbreak 3rwould 3rbecome 3ra 3rpriority 3rconcern 3rin 3rthe 3rworld. 3rOrphan 3rdiseases 3rare 3rnot
3rresearched 3rin 3ra 3rpriority 3rmanner. 3rPreclinical 3rresearch 3ris 3rnot 3romitted. 3rExtending 3rany
3rphase 3rof 3rthe 3rresearch 3rwould 3rmean3ra 3rlonger 3rtime 3rto 3rdevelop 3ra 3rvaccine. 3rThe 3rFDA 3rmust
3rensure 3rthat 3rall 3rphases 3rof 3rthe 3rpreclinical 3rand3c
r linical 3rresearch 3rphase 3r have 3r been
3rcompleted 3rin 3ra 3rsafe 3rmanner.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3r 3r 3rp. 3r7 OBJ: 3 r 5
NURSES 19TH EDITIONBY MICHELLE J. WILLIHNGANZ,
SAMUEL L. GUREVITZ, BRUCE CLAYTON COMPLETE
,Chapter 3r01: 3rDrug 3rDefinitions, 3rStandards, 3rand 3rInformation 3rSources
3rWillihnganz: 3rClayton’s 3rBasic 3rPharmacology 3rfor 3rNurses, 3r19th 3rEdition
MULTIPLE
3rCHOICE
1. Which 3rname 3ridentifies 3ra 3rdrug 3rlisted 3rby 3rthe 3rUS
3r Food 3rand3rDrug 3rAdministration 3r(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: 3r C
The 3rofficial 3rname 3ris 3rthe 3 r name 3runder 3rwhich 3ra 3rdrug
3ris 3rlisted 3rby 3rthe 3rFDA. 3rThe 3rbrand 3rname, 3ror 3rtrademark,
3ris 3rthe 3rname 3r given 3rto 3ra 3rdrug 3rby 3rits 3rmanufacturer. 3rThe
3rnonproprietary, 3ror 3rgeneric, 3rname 3ris 3rprovided 3rby 3rthe
3rUnited 3rStates 3rAdopted 3rNames 3rCouncil.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r9
OBJ: 3r1NAT: 3rNCLEX 3rClient 3rNeeds 3rCategory: 3rSafe,
3rEffective 3rCare3rEnvironment 3rTOP: 3 r Nursing 3rProcess 3rStep:
3rAssessment CON:
3rPatient 3rEducation
2. Which 3rsource 3rcontains 3rinformation 3rspecific 3rto 3rnutritional 3rsupplements?
a. USP 3rDictionary 3rof 3rUSAN 3 r &3rInternational 3rDrug 3rNames
b. Natural 3rMedicines 3rComprehensive 3rDatabase
c. United 3rStates 3rPharmacopoeia/National 3rFormulary 3r(USP 3rNF)
d. Drug 3rInteraction 3rFacts
ANS: 3r C
United 3rStates 3rPharmacopoeia/National 3rFormulary 3rcontains 3rinformation 3rspecific 3rto
3rnutritional3rsupplements. 3rUSP 3rDictionary 3rof 3rUSAN 3r & 3rInternational 3rDrug 3rNames 3ris 3ra
3rcompilation 3rof 3rdrug3rnames, 3rpronunciation 3rguide, 3rand 3rpossible 3rfuture 3rFDA 3rapproved
3rdrugs; 3rit 3rdoes 3rnot 3rinclude 3rnutritional 3rsupplements. 3r Natural 3rMedicines 3rComprehensive
3rDatabase 3rcontains
evidence-based 3rinformation 3ron 3rherbal 3rmedicines 3rand 3rherbal 3rcombination 3rproducts; 3rit
3rdoes 3rnot3i
r nclude 3rinformation 3rspecific 3rto 3rnutritional 3rsupplements. 3rDrug 3rInteraction
3rFacts 3rcontains 3rcomprehensive 3rinformation 3ron 3rdrug 3r interaction 3rfacts; 3rit 3r does 3rnot
3r include 3rnutritional 3rsupplements.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r4 OBJ:
3r33rNAT: 3 r NCLEX 3rClient 3rNeeds 3r Category: 3rPhysiological 3rIntegrity
TOP: 3 r Nursing 3rProcess 3rStep: 3rAssessment CON: 3 r Nutrition 3r| 3rPatient 3rEducation
3. Which 3rdrug 3rreference 3rcontains 3rdrug 3rmonographs 3rthat 3rdescribe 3rall 3rdrugs 3rin 3ra 3rtherapeutic 3rclass?
a. Drug 3rFacts 3rand 3rComparisons
,Test 3rBank 3rFor 3rClayton’s 3rBasic 3rPharmacology 3rfor 3rNurses 3r19th 3
3rEdition
b. Drug 3rInteraction 3rFacts
c. Handbook 3ron 3rInjectable 3rDrugs
d. Martindale—The 3rComplete 3rDrug 3rReference
ANS: 3 r A
Drug 3rFacts 3rand 3rComparisons 3rcontains 3rdrug 3rmonographs 3rthat 3rdescribe 3rall
3rdrugs 3rin 3ra3rtherapeutic 3rclass. 3rMonographs 3rare 3rformatted 3ras 3rtables 3rto 3rallow
3rcomparison 3rof 3rsimilar3p r roducts, 3rbrand 3rnames, 3rmanufacturers, 3rcost 3rindices, 3rand
3ravailable 3rdosage 3rforms 3rOnline 3rversion 3ris 3ravailable.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r4 3rTable 3r1.2
OBJ: 3r 3r 3 r 3 NAT: 3 r NCLEX 3rClient 3rNeeds 3rCategory: 3rPhysiological 3rIntegrity
TOP: 3 r Nursing 3rProcess 3rStep: 3rAssessment CON: 3 r Safety 3r| 3rPatient 3rEducation 3r| 3rClinical 3rJudgment
4. Which 3rdrug 3rreference 3rcontains 3rmonographs 3rabout 3r virtually 3revery3rsingle-entity3rdrug
available3rin 3rthe 3rUnited 3rStates 3rand 3rdescribes 3rtherapeutic 3ruses 3rof 3rdrugs, 3rincluding
3r
approved 3rand 3runapproved 3ruses?
3r
a. Martindale: 3rThe 3rComplete 3rDrug 3rReference
b. AHFS 3rDrug 3rInformation
c. Drug 3rReference
d. Drug 3rFacts 3rand 3rComparisons
ANS: 3 r B
AHFS 3rDrug 3rInformation 3rcontains 3rmonographs 3rabout 3rvirtually 3revery 3rsingle-entity 3rdrug
3ravailable 3rin 3rthe 3rUnited 3rStates 3rand 3rdescribes 3rtherapeutic 3ruses 3rof 3rdrugs, 3r including
3rapproved 3rand3u r napproved 3ruses.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r4 3rTable 3r1.2
OBJ: 3r 3r 3 r 3 NAT: 3 r NCLEX 3rClient 3rNeeds 3rCategory: 3rPhysiological 3rIntegrity
TOP: 3 r Nursing 3rProcess 3rStep: 3rPlanning CON: 3 r Safety 3r| 3rPatient 3rEducation 3r| 3rClinical 3rJudgment
5. Which 3ronline 3rdrug 3rreference 3rmakes 3ravailable 3rto 3rhealthcare 3rproviders 3rand 3rthe
3rpublic 3ra 3rstandard, 3rcomprehensive, 3rup-to-date 3rlook 3rup 3rand 3rdownloadable 3rresource
3rabout 3rmedicines?
a. American 3rDrug 3rIndex
b. American 3rHospital 3rFormulary
c. DailyMed
d. Drug 3rReference
ANS: 3r C
DailyMed 3rmakes 3ravailable 3rto 3rhealthcare 3rproviders 3rand 3rthe 3rpublic 3ra 3rstandard,
3rcomprehensive,3rup-to-date 3rlook 3rup 3rand 3rdownloadable 3rresource 3rabout 3rmedicines. 3rThe
3rAmerican 3rDrug 3rIndex 3ris3rnot 3rappropriate 3rfor 3rpatient 3ruse. 3rThe 3rAmerican 3rHospital
3rFormulary 3ris 3rnot 3rappropriate 3rfor 3rpatient 3r use. 3rThe 3rdrug 3rreference 3r is 3r not
3r appropriate 3rfor 3rpatient 3r use.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r3 3r| 3rp. 3r4 OBJ:
3r33rNAT: 3 r NCLEX 3rClient 3rNeeds 3r Category: 3rPhysiological 3rIntegrity
TOP: 3 r Nursing 3rProcess 3rStep: 3rImplementation
CON: 3 r Safety 3r| 3rPatient 3rEducation 3r| 3rClinical 3rJudgment
6. Which 3rlegislation 3rauthorizes 3rthe 3rFDA 3rto 3rdetermine 3rthe 3rsafety3rof 3ra 3rdrug 3rbefore 3rits 3rmarketing?
a. Federal 3rFood, 3rDrug, 3rand 3rCosmetic 3rAct 3r(1938)
b. Durham 3rHumphrey 3rAmendment 3r(1952)
, Test 3rBank 3rFor 3rClayton’s 3rBasic 3rPharmacology 3rfor 3rNurses 3r19th 4
3rEdition
c. Controlled 3rSubstances 3rAct 3r(1970)
d. Kefauver 3rHarris 3rDrug 3rAmendment 3r(1962)
ANS: 3 r A
The 3rFederal 3rFood, 3rDrug, 3rand 3rCosmetic 3rAct 3rof 3r1938 3rauthorized 3rthe 3rFDA 3rto
3rdetermine 3rthe 3rsafety 3rof 3rall 3rdrugs 3rbefore 3rmarketing. 3rLater 3ramendments 3rand 3racts
3rhelped 3rtighten 3rFDA 3rcontrol 3rand 3rensure 3rdrug 3rsafety. 3rThe 3rDurham 3rHumphrey
3rAmendment 3rdefines 3rthe 3rkinds 3rof 3rdrugs 3rthat 3rcannot 3rbe 3rused 3rsafely 3rwithout 3rmedical
3rsupervision 3rand 3rrestricts 3rtheir 3rsale 3rto 3rprescription 3rby 3ra 3rlicensed 3rpractitioner. 3rThe
3rControlled 3rSubstances 3rAct 3raddresses 3ronly 3rcontrolled 3rsubstances 3rand3rtheir
3rcategorization. 3rThe 3rKefauver 3rHarris 3rDrug 3rAmendment 3rensures 3rdrug 3refficacy 3rand
3rgreater3d
r rug 3rsafety. 3rDrug 3rmanufacturers 3rare 3rrequired 3rto 3rprove 3rto 3rthe 3rFDA 3rthe
3reffectiveness 3rof 3rtheir 3rproducts 3rbefore 3rmarketing 3rthem.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3rp. 3r 5 3rTable 3rl.3
OBJ: 3 r 5 NAT: 3rNCLEX 3rClient 3rNeeds 3rCategory: 3rPhysiological
3rIntegrity3T
r OP: 3 r Nursing 3rProcess 3r Step: 3rAssessment
CON: 3 r Safety 3r| 3rPatient 3rEducation 3r| 3rEvidence 3r| 3rHealth 3rCare 3rLaw
7. Which 3rclassification 3rdoes 3rmeperidine 3r(Demerol) 3rfall 3runder?
a. I
b. II
c. III
d. IV
ANS: 3 r B
Meperidine 3r(Demerol) 3ris 3ra 3rSchedule 3rII 3rdrug; 3rit 3rhas 3ra 3rhigh 3rpotential 3rfor 3rabuse 3rand
3rmay 3rlead 3rto3s
r evere 3rpsychological 3rand 3rphysical 3rdependence. 3rSchedule 3rI 3rdrugs 3rhave
3rhigh 3rpotential 3rfor 3rabuse3a
r nd 3rno 3rrecognized 3rmedical 3ruse. 3rSchedule 3rIII 3rdrugs 3rhave
3rsome 3rpotential 3rfor 3rabuse. 3rUse 3rmay 3rlead 3rto 3rlow 3rto 3rmoderate 3rphysical 3rdependence 3ror
3rhigh 3rpsychological 3rdependence. 3rSchedule 3rIV3rdrugs 3rhave 3rlow 3rpotential 3rfor 3rabuse. 3rUse
3rmay 3rlead 3rto 3rlimited 3rphysical 3ror 3rpsychological 3rdependence.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3 r p. 3r10 OBJ:
3r23rNAT: 3 r NCLEX 3rClient 3rNeeds 3rCategory: 3rSafe, 3rEffective 3rCare
3rEnvironment
TOP: 3 r Nursing 3rProcess 3rStep: 3rAssessment CON: 3 r Patient 3rEducation 3r| 3rAddiction 3r| 3rPain
8. Which 3raction 3rwould 3rthe 3rFDA 3rtake 3rto 3rexpedite 3rdrug 3rdevelopment 3r and 3rapproval 3rfor 3ran
outbreak3rof 3rsmallpox?
3r
a. List 3rsmallpox 3ras 3ra 3rhealth 3rorphan 3rdisease.
b. Omit 3rthe 3rpreclinical 3rresearch 3rphase.
c. Extend 3rthe 3rclinical 3rresearch 3rphase.
d. Fast 3rtrack 3rthe 3rinvestigational 3rdrug.
ANS: 3r D
Once 3rthe 3rInvestigational 3rNew 3rDrug 3rApplication 3rhas 3rbeen 3rapproved, 3rthe 3rdrug 3rcan
3rreceive 3rhighest 3rpriority 3rwithin 3rthe 3ragency, 3rwhich 3ris 3rcalled 3rfast 3rtracking. 3rA 3rsmallpox
3routbreak 3rwould 3rbecome 3ra 3rpriority 3rconcern 3rin 3rthe 3rworld. 3rOrphan 3rdiseases 3rare 3rnot
3rresearched 3rin 3ra 3rpriority 3rmanner. 3rPreclinical 3rresearch 3ris 3rnot 3romitted. 3rExtending 3rany
3rphase 3rof 3rthe 3rresearch 3rwould 3rmean3ra 3rlonger 3rtime 3rto 3rdevelop 3ra 3rvaccine. 3rThe 3rFDA 3rmust
3rensure 3rthat 3rall 3rphases 3rof 3rthe 3rpreclinical 3rand3c
r linical 3rresearch 3rphase 3r have 3r been
3rcompleted 3rin 3ra 3rsafe 3rmanner.
DIF: Cognitive 3rLevel: 3rKnowledge REF: 3r 3r 3rp. 3r7 OBJ: 3 r 5
